Concerns that stem cells could cause cancer in recipients are fading further with a new study

New bone formation (stained bright green under ultra-violet light) was seen in monkeys given their own reprogrammed stem cells. Courtesy of Nature magazine

A major concern over using stem cells is the risk of tumors: but now a new study shows that It takes a lot of effort to get induced pluripotent stem (iPS) cells to grow into tumors after they have been transplanted into a monkey. The findings will bolster the prospects of one day using such cells clinically in humans.

Making iPS cells from an animal's own skin cells and then transplanting them back into the creature also does not trigger an inflammatory response as long as the cells have first been coaxed to differentiate towards a more specialized cell type. Both observations, published inCell Reports today, bode well for potential cell therapies.

It's important because the field is very controversial right now, saysAshleigh Boyd,a stem-cell researcher at University College London, who was not involved in the work. It is showing that the weight of evidence is pointing towards the fact that the cells won't be rejected.

Pluripotent stem cells can be differentiated into many different specialized cell types in culture and so are touted for their potential as therapies to replace tissue lost in diseases such as Parkinsons and some forms of diabetes and blindness. iPS cells, which are made by reprogramming adult cells, have an extra advantage because transplants made from them could be genetically matched to the recipient.

Researchers all over the world are pursuing therapies based on iPS cells, and a group in Japan began enrolling patients for a human study last year. But work in mice has suggested controversially that even genetically matched iPS cellscan trigger an immune response, and pluripotent stem cells can also form slow-growing tumors, another safety concern.

Closer to human Cynthia Dunbar, a stem-cell biologist at the National Institutes of Health in Bethesda, Maryland, who led the new study, decided to evaluate both concerns in healthy rhesus macaques. Human stem cells are normally only studied for their ability to form tumors in mice as a test of pluripotency if the animals immune systems are compromised, she says.

We really wanted to set up a model that was closer to human. It was somewhat reassuring that in a normal monkey with a normal immune system you had to give a whole lot of immature cells to get any kind of tumour to grow, and they were very slow growing.

Dunbar and her team made iPS cells from skin and white blood cells from two rhesus macaques, and transplanted the iPS cells back into the monkeys that provided them. It took 20 times as many iPS cells to form a tumor in a monkey, compared with the numbers needed in an immunocompromised mouse. Such information will be valuable for assessing safety risks of potential therapies, Dunbar says. And although the iPS cells did trigger a mild immune response attracting white blood cells and causing local inflammation iPS cells that had first been differentiated to a more mature state did not.

See more here:
New Stem Cell Finding Bodes Well for Future Medical Use in Humans

May 14, 2014, 4 a.m.

STEM cell therapy is the great frontier of todays medical research.

STEM cell therapy is the great frontier of todays medical research.

While still in its infancy, stem cell technology has already moved from being a promising idea to delivering life-saving treatment for conditions such as leukaemia.

Last week about 70 people gathered at the Mid City Motel, Warrnambool, to hear about the advances from one of Australias leading researchers.

Stem cell researcher, Professor Graham Jenkin.

Professor Graham Jenkin, of the department of obstetrics and gynaecology at Monash University, is researching the use of stem cells harvested from umbilical cord blood to treat babies at risk of developing cerebral palsy as the result of oxygen deprivation during birth.

The event was hosted by the Warrnambool branch of the Inner Wheel Club as part of a national fund-raising program by the organisation.

Professor Jenkin, deputy director of The Ritchie Centre, said treating infants deprived of oxygen with cord blood stem cells was showing promising results in preventing the brain damage that leads to cerebral palsy.

We are looking at treating infants within a 24-hour window after birth, Professor Jenkin said. We would be aiming for treatment after about six hours if possible, which is about as soon as the stem cells can be harvested.

See the original post here:
Stem cell research offers new hope

Image Caption: Researchers use modified RNA transfection to correct genetic dysfunction in heart stem cells derived from Barth syndrome patients. The series of images show how inserting modified RNA into diseased cells causes the cells to produce functioning versions of the TAZ protein (first image: in green) that correctly localize in the mitochondria (second image: in red). When the images are merged to demonstrate this localization, green overlaps with red, giving the third image a yellow color. Credit: Gang Wang and William Pu/Boston Children's Hospital

[ Watch The Video: Cardiac Tissue Contractile Strength Differences Shown Using Heart-On-A-Chip ]

Harvard University

Harvard scientists have merged stem cell and organ-on-a-chip technologies to grow, for the first time, functioning human heart tissue carrying an inherited cardiovascular disease. The research appears to be a big step forward for personalized medicine, as it is working proof that a chunk of tissue containing a patients specific genetic disorder can be replicated in the laboratory.

The work, published in Nature Medicine, is the result of a collaborative effort bringing together scientists from the Harvard Stem Cell Institute, the Wyss Institute for Biologically Inspired Engineering, Boston Childrens Hospital, the Harvard School of Engineering and Applied Sciences, and Harvard Medical School. It combines the organs-on-chips expertise of Kevin Kit Parker, PhD, and stem cell and clinical insights by William Pu, MD.

Using their interdisciplinary approach, the investigators modeled the cardiovascular disease Barth syndrome, a rare X-linked cardiac disorder caused by mutation of a single gene called Tafazzin, or TAZ. The disorder, which is currently untreatable, primarily appears in boys, and is associated with a number of symptoms affecting heart and skeletal muscle function.

The researchers took skin cells from two Barth syndrome patients, and manipulated the cells to become stem cells that carried these patients TAZ mutations. Instead of using the stem cells to generate single heart cells in a dish, the cells were grown on chips lined with human extracellular matrix proteins that mimic their natural environment, tricking the cells into joining together as they would if they were forming a diseased human heart. The engineered diseased tissue contracted very weakly, as would the heart muscle seen in Barth syndrome patients.

The investigators then used genome editinga technique pioneered by Harvard collaborator George Church, PhDto mutate TAZ in normal cells, confirming that this mutation is sufficient to cause weak contraction in the engineered tissue. On the other hand, delivering the TAZ gene product to diseased tissue in the laboratory corrected the contractile defect, creating the first tissue-based model of correction of a genetic heart disease.

You dont really understand the meaning of a single cells genetic mutation until you build a huge chunk of organ and see how it functions or doesnt function, said Parker, who has spent over a decade working on organs-on-chips technology. In the case of the cells grown out of patients with Barth syndrome, we saw much weaker contractions and irregular tissue assembly. Being able to model the disease from a single cell all the way up to heart tissue, I think thats a big advance.

Furthermore, the scientists discovered that the TAZ mutation works in such a way to disrupt the normal activity of mitochondria, often called the power plants of the cell for their role in making energy. However, the mutation didnt seem to affect overall energy supply of the cells. In what could be a newly identified function for mitochondria, the researchers describe a direct link between mitochondrial function and a heart cells ability to build itself in a way that allows it to contract.

Read the original:
'Heart Disease-On-A-Chip' Made From Patient Stem Cells

Beware of fake medicines and advertisements touting the purported miracles that stem cell therapy can do. This was the warning aired by former health secretary Esperanza Cabral at the Kapihan sa Manila at the Diamond Hotel last Monday.

Contrary to what the ads claim, she said, stem cell therapy has not been scientifically proven to cure any disease or make anyone young again. It has been successful in a very few experiments, which is the reason quack doctors are taking advantage of it to make exaggerated claims that the therapy can cure the deadliest diseases known to man.

The Food and Drug Administration (FDA) very recently issued a similar warning against it.

Stem cell therapy is the process of injecting into patients young cells taken from humans or sheep. The theory is that the young cells will rejuvenate the old cells of the patients and make them young again and cure whatever diseases they have. Although experiments are being conducted, no such results have been achieved. But that does not prevent foreign quack doctors from coming here and making all those exaggerated claims. Sadly, they are aided by some Filipino doctors.

The reason is that in countries like the Philippines where the people are suckers for miracle cures, stem cell therapyand other miracle curesis like a gold mine.

Aging millionaires looking for the fountain of youth pay a lot of money to undergo stem cell therapy. Patients with terminal illnesses like cancer, in a desperate search for a cure, also fall victim to the sales talk and word-of-mouth yarns of so-and-so being cured by the therapy.

But they get neither younger nor cured. And the quack doctors run laughing with their patients money all the way to the bank.

A friend told me that he had gone abroad to have stem cell therapy. He said he felt better and stronger after the treatment. Look at me, dont I look younger? he said.

I looked at him. He didnt look a minute younger and in fact looked the same as when I last saw him, maybe even older.

My wife said I look younger, he said. It was his wife who had convinced him to have the stem cell therapy.

Read the original post:
Dont be fooled by quacks and fake meds

We put up with dry, itchy skin and are constantly applying creams to try (in vain) to fight the flake - but there might be some much needed good news for us eczema sufferers.

New research suggests eczema sufferers may have less chance of developing skin cancer.

A study conducted by experts at King's College London found the immune response triggered by eczema could stop tumours forming by shedding potentially cancerous cells.

Genetically engineered mice lacking three skin proteins - known as "knock-out" mice - were used to replicate some of the skin defects found in eczema sufferers.

Cancer-causing chemicals were tested on normal mice and the knock-out mice. Researchers found the number of benign tumours per mouse was six times lower in knock-out mice.

The new study, published in eLife, suggests both types of mice were equally susceptible to getting cancer-causing mutations, but an exaggerated inflammatory reaction in knock-out mice led to enhanced shedding of potentially cancerous cells from the skin.

Professor Fiona Watt, director of the centre for stem cells and regenerative medicine at King's College London, said: "We are excited by our findings as they establish a clear link between cancer susceptibility and an allergic skin condition in our experimental model.

"They also support the view that modifying the body's immune system is an important strategy in treating cancer.

"I hope our study provides some small consolation to eczema sufferers - that this uncomfortable skin condition may actually be beneficial in some circumstances."

View post:
Eczema Could Reduce The Risk Of Skin Cancer, Research Shows

Human embryonic stem cells can become any cell in the body. AFP FILE PHOTO

MANILA, Philippines Health authorities warned the public anew on Saturday about health facilities and medical practitioners offering unauthorized stem cell therapy and products.

In an advisory, the Food and Drug Administration said that to date, not one stem cell or human cells, tissues, and cellular and tissue-based products (HCT/Ps) that applied for registration has been registered by the FDA for compassionate or clinical trial use, or general use.

The use of HCT/Ps without the authorization or permission by the FDA is considered illegal, it said, reminding hospitals and health facilities of the provisions of the FDA Act of 2009, which prohibits the manufacture, use, advertisement or sponsorship of unregistered health products.

This warning extends to all unlicensed practitioners from other countries and to tourists who visit the Philippines for leisure and medical needs, the advisory added.

According to FDA acting director general Kenneth Hartigan Go, the FDA recognizes only hematopoietic (pertaining to the formation and development of blood cells) stem cell transplantation, corneal resurfacing with limbal stem cells and skin regeneration with epidermal stem cells as generally accepted standards of health care procedures.

If health institutions are doing these three procedures, they can continue doing them because those are allowed. Go said, adding that the efficacy of the use of stem cells for the treatment of other diseases, such as diabetes, cancer and autism, among others, has yet to be proven.

Go noted that while many spa centers and salons are advertising stem cell therapy and products, none of them has the approval of the health agency.

As of now we have not accredited any health facility offering stem cell therapy yet, Go said.

Several facilities had applied for accreditation but Go said many of these were asked to correct their deficiencies.

Read this article:
Public warned of fly-by-night stem cell procedures, products

Skin cells from infertile men can be turned into the precursors of sperm cells in a lab, according to a new study.

The findings raise the possibility of one day making sperm from the skin cells of men with fertility problems, the researchers said. However, much more research is needed to determine if this is possible and whether it is safe.

In the new study, researchers first transformed the men's skin cells into stem cells, then implanted the cells into the testes of mice where they formed sperm precursor cells. However, one safety issue is that some of the stem cells formed tumors in the mice, said study researcher Renee Reijo Pera, who conducted the work while at Stanford University, and is now a professor of cell biology and neurosciences at Montana State University.

To conduct the study, Pera and colleagues took skin samples from three infertile men, and two fertile men. The infertile men had a genetic mutation in a region of the genome called AZF1 that prevented them from making mature sperm, a condition called azoospermia. [Sexy Swimmers: 7 Facts About Sperm]

The researchers used the skin cells to produce what are called induced pluripotent stem cells (iPS cells), which have the ability to become nearly any tissue type in the body. These iPS cells were then implanted into the testes of mice, where they turned into germ cells, which normally give rise to sperm in males.

However, in the study, the germ cells did not go on to form mature sperm in the mice, likely because of evolutionary differences between humans and mice that blocked the production of such mature cells, Pera said.

The stem cells from fertile men were much better at generating germ cells than those from infertile men. Still, the fact that the infertile men's stem cells produced germ cells at all was surprising, because men with the AZF1 mutation often have no germ cells, Pera said.

The new findings suggest that these infertile men do in fact have the potential to produce germ cells, but the germ cells are lost over time, Pera said. If that's true, young boys with this mutation might be able to preserve their germ cells for the future by collecting and freezing samples of testes tissue, Pera said.

The mouse model used in the study will help researchers better understand the earliest stages of sperm development, Pera said. For example, the cells of human embryo "decide" whether they are going to be germ cells at day 12 after conception, she said. "We've developed a way to study the earliest steps," which take place in the fetus, Pera said.

Previously, the same group of researchers created germ cells from human embryonic stem cells. And last year, experiments in mice showed that skin cells of the animals can be turned into stem cells, which can then be turned into germ cells. When researchers implanted these germ cells in sterile mice, the mice became fertile.

Follow this link:
Skin cells turned into sperm

Topics: editors picks, family, relationships, science, sex

INFERTILE men could in future be offered a new form of treatment based on converting their skin cells into the sperm-making tissue that is missing in their testicles, scientists have said.

A study has found that it is possible to convert skin cells into male "germ cells" which are responsible for sperm production, using an established technique for creating embryonic-like stem cells, in a form of genetic engineering.

The research, published in the journal Cell Reports, showed that stem cells derived from human skin become active germ cells when transplanted into the testes of mice - even when the man suffers from a genetic condition where he lacks functioning germ cells in his own testes.

Although the mice had functioning human male germ cells, they did not produce human sperm, said Renee Reijo Pera, of Montana State University, who led the study.

"There is an evolutionary block that means that when germ cells from one species are transferred to another, there is not full spermatogenesis unless the species are very closely related," she added.

View post:
Skin cells provide new hope for infertile men

Chaiwat Subprasom/Reuters/Corbis

Many companies around the world offer stem-cell treatments to patients with heart disease.

An analysis of clinical studies that use adult stem cells to treat heart disease has raised questions about the value of a therapy that many consider inappropriately hyped.

Early-phase clinical trials have reported that adult stem cells are effective in treating heart attack and heart failure, and many companies are moving quickly to tap into this potentially lucrative market. But a comprehensive study that looked at discrepancies in trials investigating treatments that use patients own stem cells, published this week in the journal BMJ (ref. 1), finds that only trials containing flaws, such as design or reporting errors, showed positive outcomes. Error-free trials showed no benefit at all.

The publication comes as two major clinical trials designed to conclusively test the treatments efficacy are recruiting thousands of patients.

The BMJ paper is concerning because the therapeutic approach is already being commercialized, argues stem-cell researcher Paolo Bianco at the Sapienza University of Rome. Premature trials can create unrealistic hopes for patients, and divert resources from the necessary basic studies we need to design more appropriate treatments.

Therapies that use adult stem cells typically involve collecting mesenchymal stem cells from bone marrow taken from the patients hip bone. The cells are then injected back into the patient, to help repair damaged tissue. Original claims that they differentiated into replacement cells have been rejected2, and many clinicians now believe that the cells act by releasing molecules that cause inflammation, with an attendant growth of oxygen-delivering small blood vessels, in the damaged tissue.

The approach has spawned international commercialization of various forms of the therapy, with companies offering treatments for disorders ranging from Parkinsons disease to heart failure. But the effectiveness of such therapies remains unproven.

I have a lot of hope for regenerative medicine, but our results make me fearful.

The BMJ study, led by cardiologist Darrel Francis at Imperial College London, examined 133 reports of 49 randomized clinical trials published up to April last year, involving the treatment of patients who had had a heart attack or heart failure. It included all accessible randomized studies, and looked for discrepancies in design, methodology and reporting of results.

Excerpt from:
Doubts over heart stem-cell therapy

Researchers hope stem cells could one day treat chronic conditions like diabetes and Parkinsons disease.

Healthy bloom: Insulin, shown in red, is being produced by cells that started as embryonic stem cells derived from a patient with type 1 diabetes.

A series of breakthroughs in cloning technology over the last year and a half are stoking hopes that cells could be used as treatments for patients with chronic, debilitating diseases such as diabetes and Parkinsons.

In January 2013, researchers at the Oregon Health and Science University reported that they had successfully created embryonic stem cells from a human embryo formed when the nucleus of one persons cell was transferred into another persons egg that had its original nucleus removed (see Human Embryonic Stem Cells Cloned). That was the first time stem cells had been made from such a cloned embryo, and the advance provides a potential route by which scientists could create various kinds of replacement cells based on a patients own genome. Many other research teams are pursuing another method of creating stem cells from a patients own cells, but some believe cells made with the cloning technique could be more likely to develop into a wide variety of cell types.

In the most recent advance for the cloning-based approach, a new report describes stem cells produced by cloning a skin cell from a woman with type 1 diabetes. The researchers were then able to turn those stem cells into insulin-producing cells resembling the beta cells that are lost in that disease. The immune system attacks these pancreatic cells, leaving patients unable to properly regulate their blood sugar levels.

Susan Solomon, a coauthor of the new study and cofounder of the New York Stem Cell Foundation (NYSCF), told reporters the results are an important step forward in our quest to develop healthy patient-specific stem cells to be used to replace cells that are diseased or dead.

The ultimate idea is to treat diabetes with insulin-producing cells made from a patients own cells and a donated egg. Currently, insulin-producing cells harvested from a cadaver are transplanted into some diabetes patients. But patients treated this way must take immunosuppressing drugs, and the number of cadaver cells is limited.

The cloned cells are thought to be better accepted by the immune system. But given that the body attacks its own beta cells, how can researchers prevent the immune destruction of the transplants? Its very difficult, says Solomon. We are acutely aware of the need to address both sides of the problem.

There are also regulatory issues surrounding the cloning method. Lead researcher and coauthor Dieter Egli began the research at Harvard University but moved it to the New York institution because Massachusetts restrictions on egg donation prevented the work from progressing.

Egg supply is another challenge. The cloning works about 10 percent of the time, and only three of the four cloned embryos in the experiment led to viable stem-cell lines. When you think about wider application of this technology for patients with diabetes, cardiovascular disease, [and others], you are talking about hundreds of millions of people, says Robert Lanza, a stem-cell pioneer at Advanced Cell Technology and coauthor of a recent cloning report. When you start talking about numbers like that, its just not going to be practical to use these cells in that patient-specific way.

Follow this link:
Stem Cells from a Diabetes Patient

Scientists have taken skin cells from a woman suffering from type 1 diabetes, reprogrammed them into embryonic stem cells, and then converted those cells into insulin-producing cells in mice, according to a new study.

The announcement, which comes soon after another stem cell success involving therapeutic cloning, was published Monday in the journal Nature.

"This advance brings us a significant step closer to the development of cell replacement therapies," said senior study author Dieter Egli, a researcher at the New York Stem Cell Foundation.

Embryonic stem cells, or pluripotent cells, are cells that can reproduce endlessly and transform themselves into any type of human tissue. Researchers hope that the cells will one day be used to create transplant tissues that will not be rejected by the patient's body, because they carry their own DNA.

Egli and his colleagues used a cloning technique known as somatic cell nuclear transfer, or SCNT -- a process similar to the one used to clone "Dolly" the sheep in 1996.

The process involves removing the nucleus from a human egg cell, replacing it with the nucleus from a foreign "donor" cell, and then allowing the egg to divide and develop for a period of days. The developing embryo will contain a mass of pluripotent cells, which are removed and used to create a line of reproducing cells.

If the cloned embryo were implanted in the womb of a surrogate mother -- an act scientists consider unethical for a number of reasons -- it could possibly develop into a baby.

Up until now, the stem cell field has relied on a very different method of pluripotent cell production called induced pluripotency. The process is viewed as being much easier than SCNT, because it does not involve the controversial use of human egg cells, which are also difficult to obtain.

At a news conference, Egli told reporters that the SCNT process was becoming increasingly refined and should be viewed as a reliable source of pluripotent cells.

"For me this is the way to go," Egli said. "This is about reprogramming a patient's own cells, with their own genotype, with their own DNA that are immunologically matched to them and no one else, essentially. I think this is going to become a reality."

See original here:
Scientists report another embryonic cloning success

Regenerative medicine took a step forward on Monday with the announcement of the creation of the first disease-specific line of embryonic stem cells made with a patient's own DNA.

These cells, which used DNA from a 32-year-old woman who had developed Type-1 diabetes at the age of ten, might herald the daystill far in the futurewhen scientists replace dysfunctional cells with healthy cells identical to the patient's own but grown in the lab.

The work was led by Dieter Egli of the New York Stem Cell Foundation (NYSCF) and was published Monday in Nature.

"This is a really important step forward in our quest to develop healthy, patient-specific stem cells that can be used to replace cells that are diseased or dead," said Susan Solomon, chief executive officer of NYSCF, which she co-founded in 2005 partly to search for a cure for her son's diabetes.

Stem cells could one day be used to treat not only diabetes but also other diseases, such as Parkinson's and Alzheimer's.

Embryonic Stem Cells Morph Into Beta Cells

In Type 1 diabetes, the body loses its ability to produce insulin when insulin-producing beta cells in the pancreas become damaged. Ideally this problem could be corrected with replacement therapy, using stem cells to create beta cells the body would recognize as its own because they contain the patient's own genome. This is the holy grail of personalized medicine.

To create a patient-specific line of embryonic stem cells, Egli and his colleagues used a technique known as somatic cell nuclear transfer. They took skin cells from the female patient, removed the nucleus from one cell and then inserted it into a donor egg cellan oocytefrom which the nucleus had been removed.

They stimulated the egg to grow until it became a blastocyst, a hundred-cell embryo in which some cells are "pluripotent," or capable of turning into any type of cell in the body. The researchers then directed a few of those embryonic stem cells to become beta cells. To their delight, the beta cells in the lab produced insulin, just as they would have in the body.

This research builds on work done last year in which scientists from the Oregon Health and Science University used the somatic cell nuclear transfer technique with skin cells from a fetus. It also advances previous work done by Egli and his colleagues in 2011, in which they created embryonic stem cell lines with an extra set of chromosomes. (The new stem cells, and the ones from Oregon, have the normal number of chromosomes.)

Originally posted here:
Scientists Create Personalized Stem Cells, Raising Hopes for Diabetes Cure

New York, NY (PRWEB) April 29, 2014

The Stem Cell Institute located in Panama City, Panama, welcomes special guest speaker Roberta F. Shapiro, DO, FAAPM&R to its public seminar on umbilical cord stem cell therapy on Saturday, May 17, 2014 in New York City at the New York Hilton Midtown from 1:00 pm to 4:00 pm.

Dr. Shapiro will discuss A New York Doctors Path to Panama.

Dr. Shapiro operates a private practice for physical medicine and rehabilitation in New York City. Her primary professional activities include outpatient practice focused on comprehensive treatment of acute and chronic musculoskeletal and myofascial pain syndromes using manipulation techniques, trigger point injections, tendon injections, bursae injections, nerve and motor point blocks. Secondary work at her practice focuses on the management of pediatric onset disability.

She is the founder and president of the Dayniah Fund, a non-profit charitable foundation formed to support persons with progressive debilitating diseases who are faced with catastrophic events such as surgery or illness. The Dayniah Fund educates the public about the challenges of people with disabilities and supports research on reducing the pain and suffering caused by disabling diseases and conditions.

Dr. Shapiro serves as assistant clinical professor in the Department of Rehabilitation and Regenerative Medicine at Columbia University Medical Center.

Stem Cell Institute Speakers include:

Neil Riordan PhD Clinical Trials: Umbilical Cord Mesenchymal Stem Cell Therapy for Autism and Spinal Cord Injury

Dr. Riordan is the founder of the Stem Cell Institute and Medistem Panama Inc.

Jorge Paz-Rodriguez MD Stem Cell Therapy for Autoimmune Disease: MS, Rheumatoid Arthritis and Lupus

Read more:
Stem Cell Institute Welcomes Special Guest Speaker Roberta F. Shapiro DO, FAAPM&R to Stem Cell Therapy Public Seminar ...

Stem Cell Therapy | Genetics and Rheumatoid Arthritis
What do genes have to do with arthritis? No... not those kinds of genes... these kinds of jeans. Genetics can explain why infections can trigger rheumatoid arthritis Appearing in Science Codex...

By: Nathan Wei

See the article here:
Stem Cell Therapy | Genetics and Rheumatoid Arthritis - Video

2020 Stem Cell Therapy Market Alternative Strategies
Read more at http://www.reportsnreports.com/reports/281584-stem-cell-therapy-market-by-treatment-mode-autologous-allogeneic-therapeutic-applications-cns-cvs-...

By: paul harris

Visit link:
2020 Stem Cell Therapy Market Alternative Strategies - Video

Wounded Warrior severe low back pain 3 months after stem cells by Dr Harry Adelson
Seven years ago while serving in Special Forces in Afghanistan, Ben was hit directly in the chest by a Rocket-Propelled-Grenade which slammed him against a wall and crushed his spine. THEN...

By: Harry Adelson, N.D.

Excerpt from:
Wounded Warrior severe low back pain 3 months after stem cells by Dr Harry Adelson - Video

Home > News > health-news

Bangalore, Apr 22 : City-based Narayana Health City (NHC) with over 300 successful Bone Marrow Transplants to its credit, today show cased the efficacy of this treatment modality with over 80 per cent success rate for curing cancerous and genetic blood diseases.

The two types of diseases which can be cured by bone marrow transplant are Leukemia, Severe Aplastic Anemia, Thassemia and Immune Deficiency Disorders.

Bone marrow transplant is a highly advanced procedure that involves transfusion of bone marrow stem cells from a healthy donor to a patient.

Speaking to reporters here, Dr Sharat Damodar, HoD and Senior Consultant Hematologist, Bone marrow transplant unit at NHC said the nature of blood diseases/disorders is either genetic in nature or acquired due to exposure to several risk factors including hazardous environment and consumption of adulterated food.

"Bone marrow transplants are now producing high success rates as it is curative in nature and offers hope to patients of a life beyond painful and fatal diseases," he said.

Dr Damodar, however, regretted that most of bone transplants are now done using bone marrow stem cells from blood relatives of the patients. "In India it is a challenge to find donors and we should consider it as our social responsibility to volunteer for donating healthy bone marrow and help patients in need," he added.

He said the government had recently opened donor registry DATRI and 50,000 people had enrolled into it.

"Compared to a population of 126 crore, we have just 50,000 donors. This is in comparison to an European country like Germany you can find millions of them," he added.

Dr Damodar and his team of experts also presented and shared the cases of patients who have been in remission for five years and leading a disease free life post bone marrow transplantation.

See more here:
NHC showcase bone marrow transplant to cure blood disorders

The advance could lead to tissue-transplant operations for a range of debilitating disorders, such as Parkinson's disease, multiple sclerosis, heart disease and spinal cord injuries.

Last year, a team created stem cells from the skin cells of babies, but it was unclear whether it would work in adults.

However, a team of scientists from the Research Institute for Stem Cell Research at CHA Health Systems in Los Angeles and the University of Seoul said they had achieved the same result with two men, one aged 35, the other the 75-year-old. "The proportion of diseases you can treat with lab-made tissue increases with age. So if you can't do this with adult cells it is of limited value," said Robert Lanza, co-author of the research, which was published in the journal Cell Stem Cell.

The technique works by removing the nucleus from an unfertilised egg and replacing it with the nucleus of a skin cell. An electric shock causes the cells to divide until they form a "blastocyst", a small ball of a few hundred cells.

In IVF, a blastocyst is implanted into the womb, but with the new technique the cells would be harvested to create other organs or tissues.

The breakthrough is likely to reignite the debate about the ethics of creating human embryos for medical purposes and the possible use of the same technique to produce cloned babies - which is illegal in Britain.

Although the embryos created may not produce a human clone even if implanted in a womb, the prospect is now closer. However, scientists have tried for years to clone monkeys and have yet to succeed.

Dr Lanza admitted that without strong regulations, the early embryos produced in therapeutic cloning "could also be used for human reproductive cloning, although this would be unsafe and grossly unethical". However, he said it was important for the future of regenerative medicine that research into therapeutic cloning should continue.

Shoukhrat Mitalipov, a reproductive biologist from Oregon Health and Science University, who developed the technique last year, said: "The advance here is showing that [nuclear transfer] looks like it will work with people of all ages.

"I'm happy to hear that our experiment was verified and shown to be genuine."

Go here to see the original:
Cloning advance means human tissues could be regrown, even in old age

stem cell therapy treatment for cerebral palsy with mental retardation with low vision by dr alok
improvement seen in just 3 months after stem cell therapy treatment for cerebral palsy with mental retardation with low vision by dr alok sharma, mumbai, ind...

By: Neurogen Brain and Spine Institute

Originally posted here:
stem cell therapy treatment for cerebral palsy with mental retardation with low vision by dr alok - Video

Marie McCullough, Inquirer Staff Writer Last updated: Sunday, April 20, 2014, 8:51 AM Posted: Saturday, April 19, 2014, 4:05 PM

Mason Shaffer was seven months old when doctors treated him for a fatal genetic bone disorder by destroying his blood and immune systems and rebuilding them with donated blood stem cells.

That's when his parents, Sarah and Marc Shaffer of Lansdowne, learned about a fairly unsung medical trend: public, nonprofit facilities that collect, store, and distribute blood from donated umbilical cords. The stem cells that saved Mason, now a healthy 5-year-old, were in cord blood.

Nonprofit cord-blood banking is a complicated, costly network, but it has been growing steadily, thanks to federal support, stem-cell research - and families like the Shaffers.

Sarah and Marc discovered that in the Philadelphia area, even if parents realized umbilical cords were more than just waste products of childbirth, there was no easy way to donate the tissue. So they established the Mason Shaffer Foundation to change that.

This month, Temple University Hospital launched a program in collaboration with the foundation and the New Jersey Cord Blood Bank to educate expectant parents and enable them to donate in a convenient way - at no charge to them or Temple. The foundation provides the educational material, and the cord-blood bank covers the collection costs, which are offset by health insurance reimbursement for transplants.

Three years ago, Lankenau Medical Center in Wynnewood became the foundation's first cord-blood donation center.

Temple, however, is expected to help fill the desperate need for a more racially diverse cord-blood stockpile. That need was recognized by the federal Stem Cell Therapeutic and Research Act of 2005, which included funding that will help underwrite the first year of Temple's program.

Of the 3,200 babies delivered at Temple each year, 65 percent are African American, and 30 percent are Hispanic.

Read more here:
Umbilical cord blood transplants become standard